BioAv Cancer Research Results

BioAv, bioavailability: Click to Expand ⟱
Source:
Type: measurement
Bioavailability (usually in %) absorbed by the body.
CRC, Colorectal Cancer: Click to Expand ⟱
Colorectal cancer is a broader term that encompasses both colon and rectal cancer.
Scientific Papers found: Click to Expand⟱
2678- BBR,    Berberine as a Potential Agent for the Treatment of Colorectal Cancer
- Review, CRC, NA
*Inflam↓, *antiOx↑, *cardioP↑, *neuroP↑, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDC2↓, AMPK↝, mTOR↝, Casp8↑, Casp9↑, Cyt‑c↑, TumCMig↓, TumCI↓, EMT↓, MMPs↓, E-cadherin↓, Telomerase↓, *toxicity↓, GRP78/BiP↓, EGFR↓, CDK4↓, COX2↓, PGE2↓, p‑JAK2↓, p‑STAT3↓, MMP2↓, MMP9↓, GutMicro↑, eff↝, *BioAv↓, BioAv↑,
5823- capec,    Capecitabine: a review
- Review, CRC, NA
eff↑, BioAv↑, eff↑,
5981- Chit,    Chitosan-Based Drug Delivery Systems for Targeted Chemotherapy in Colorectal Cancer: A Scoping Review
- Review, CRC, NA
DDS↑, eff↑, BioAv↑, BioEnh↑, eff↑,
7013- Fuc,    Fucoidan-based nanoparticles for colorectal cancer therapy: Mechanisms and preclinical insights
- Review, CRC, NA
*Inflam↓, *antiOx↑, AntiCan↑, BioAv↑, Apoptosis↑, angioG↓, Imm↝, ChemoSen↑, chemoP↑,
3138- VitC,    The Hypoxia-inducible Factor Renders Cancer Cells More Sensitive to Vitamin C-induced Toxicity
- in-vitro, RCC, RCC4 - in-vitro, CRC, HCT116 - in-vitro, BC, MDA-MB-435 - in-vitro, Ovarian, SKOV3 - in-vitro, Colon, SW48 - in-vitro, GBM, U251
eff↑, Warburg↓, BioAv↑, ROS↑, DNAdam↑, ATP↓, eff↑, necrosis↑, PARP↑,

Showing Research Papers: 1 to 5 of 5

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

ROS↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↓, 1,   CDC2↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↝, 1,   Warburg↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,   Casp8↑, 1,   Casp9↑, 1,   Cyt‑c↑, 1,   necrosis↑, 1,   Telomerase↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

GRP78/BiP↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,   PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK4↓, 1,   cycD1/CCND1↓, 1,   cycE/CCNE↓, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

EMT↓, 1,   mTOR↝, 1,   p‑STAT3↓, 1,  

Migration(tgid=13) ⓘ

E-cadherin↓, 1,   MMP2↓, 1,   MMP9↓, 1,   MMPs↓, 1,   TumCI↓, 1,   TumCMig↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   EGFR↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 1,   Imm↝, 1,   p‑JAK2↓, 1,   PGE2↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 5,   BioEnh↑, 1,   ChemoSen↑, 1,   DDS↑, 1,   eff↑, 6,   eff↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 1,   GutMicro↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   chemoP↑, 1,  
Total Targets: 43

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 1,   neuroP↑, 1,   toxicity↓, 1,  
Total Targets: 6

Scientific Paper Hit Count for: BioAv, bioavailability
1 Berberine
1 capecitabine
1 chitosan
1 Fucoidan
1 Vitamin C (Ascorbic Acid)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:6  Cells:%  prod#:%  Target#:792  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page